NCT04130958 Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
| NCT ID | NCT04130958 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Major Depressive Episode |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-11-01 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).
Eligibility Criteria
Inclusion Criteria: * 18-65 years of age * Diagnosed with BPD or MDE * Chief complaint of suicidal thoughts and behaviors Exclusion Criteria: * Neurological conditions with known structural brain lesion * Prior neurosurgical procedure * Metal in the body that is ferromagnetic or metal injury to the eyes * Epilepsy * Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt * Psychopathology not appropriate for the treatment (e.g., manic episode or psychosis) * Current alcohol dependence or active symptoms of non-alcohol psychoactive substance use withdrawal, as indicated by self-report * Inability to meet the safety criteria for MRI scanning according to the protocols of the MGH Department of Radiology * Current pregnancy
Contact & Investigator
Joan Camprodon, MD/PhD
PRINCIPAL INVESTIGATOR
6177265348
Frequently Asked Questions
Who can join the NCT04130958 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Major Depressive Episode. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04130958 currently recruiting?
Yes, NCT04130958 is actively recruiting participants. Contact the research team at mghdnn@mgh.harvard.edu for enrollment information.
Where is the NCT04130958 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT04130958 clinical trial?
NCT04130958 is sponsored by Massachusetts General Hospital. The principal investigator is Joan Camprodon, MD/PhD at 6177265348. The trial plans to enroll 80 participants.